Incidence of cardiac events slightly higher with trastuzumab
the ONA take:
The cumulative incidence of cardiac events (CE) at 6 years was slightly higher in patients with HER2-positive early breast cancer receiving trastuzumab, a new study published online ahead of print in the Journal of Clinical Oncology has shown.
For the study, patients received adjuvant doxorubicin plus cyclophosphamide followed by either weekly paclitaxel (arm A), paclitaxel then trastuzumab (arm B), or paclitaxel plus trastuzumab followed by trastuzumab alone (arm C).
Results showed that the cumulative incidence of cardiac events was 0.6% in arm A, 2.8% in arm B, and 3.4% in arm C.
Researchers found that left ventricular ejection fraction (LVEF) recovered in the majority of patients that developed congestive heart failure.
The study also demonstrated that age 60 years or older, LVEF <65% at baseline, and use of antihypertensive medications were associated with an increased risk of cardiac events in patients receiving trastuzumab.
“The cumulative incidence of CE at 6 years was slightly higher with the addition of trastuzumab; however, the late development of CE is infrequent,” the authors conclude. “Trastuzumab (in the context of anthracycline- and taxane-based therapy) continues to have a favorable benefit-risk ratio.”
The cumulative incidence of cardiac events (CE) at 6 years was slightly higher in patients with HER2-positive early breast cancer receiving trastuzumab.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
- Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated
- VBPWPs Can Compliment Patient Management in Clinical Trials
- Communication Technology Improves Treatment Burden, Patient Perspective of Oncology Care
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|